Adaptimmune Therapeutics PLC expected to post earnings of 14  cents a share - Earnings Preview

Adaptimmune Therapeutics

11/03/2022 14:30

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 14. 
    * The Abingdon Oxfordshire-based  company is expected to
report  a
6,321.4% increase in revenue to $96.45 million from $1.5 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Adaptimmune
Therapeutics
PLC is for earnings of 14 cents per share. For the same quarter
last year, the company reported a loss of 24 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $9​, above​ its last closing price of $1.89.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.26       -0.26      -0.30     Missed  -13.2
 Jun. 30 2021  -0.24       -0.24      -0.24     Met     2
 Mar. 31 2021  -0.25       -0.25      -0.24     Beat    4​
 Dec. 31 2020  -0.23       -0.23      -0.24     Missed  -3.3
 ​​Sep.        -0.25       -0.25      -0.24     Beat    5.5
 30 2020                                                
 Jun. 30 2020  -0.24       -0.24      -0.24     Met     -2​
 Mar. 31 2020  -0.26       -0.25      -0.24     Beat    5.3
 Dec. 31 2019  -0.33       -0.34      -0.30     Beat    11.9
 This summary was machine generated March 11 at 14:30 GMT.  All
figures in US dollars  unless otherwise stated